CIK 0001048477
- Large accelerated filer
BIOMARIN PHARMACEUTICAL INC
Sign in to watch- Ticker
- BMRN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680397820
- Phone
- +1 415-506-6700
- Business address
- 105 DIGITAL DRIVE, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,466,459
- in 2 filings
Net −$1,466,459. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-15 | FUCHS HENRY J President, Worldwide R&D | Grant or award · Stock Option (Right to buy Common Stock) | +37,710 | 37,710 | ||
| 2021-03-15 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Grant or award | +10,720 | 72,001 | ||
| 2021-03-15 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Shares withheld for taxes | −5,273 | $78.39 | $413K | 66,728 |
| 2021-03-15 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Grant or award · Stock Option (Right to buy Common Stock) | +26,400 | 26,400 | ||
| 2021-03-15 | BIENAIME JEAN JACQUES Chief Executive Officer | Grant or award | +41,350 | 337,002 | ||
| 2021-03-15 | BIENAIME JEAN JACQUES Chief Executive Officer | Shares withheld for taxes | −23,426 | $78.39 | $1.8M | 313,576 |
| 2021-03-15 | BIENAIME JEAN JACQUES Chief Executive Officer | Grant or award · Stock Option (Right to buy Common Stock) | +101,820 | 101,820 | ||
| 2021-03-15 | Acosta Andrea GVP, Chief Accounting Officer | Grant or award | +4,290 | 19,068 | ||
| 2021-03-15 | Acosta Andrea GVP, Chief Accounting Officer | Shares withheld for taxes | −553 | $78.39 | $43K | 18,515 |
| 2021-03-15 | Acosta Andrea GVP, Chief Accounting Officer | Grant or award · Stock Option (Right to buy Common Stock) | +5,280 | 5,280 | ||
| 2021-03-12 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion | +7,000 | $26.49 | $185K | 302,652 |
| 2021-03-12 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale | −7,000 | $77.10 | $540K | 295,652 |
| 2021-03-12 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to buy Common Stock) | −7,000 | 78,513 | ||
| 2021-03-11 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion | +7,000 | $26.49 | $185K | 302,652 |
| 2021-03-11 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale | −7,000 | $77.68 | $544K | 295,652 |
| 2021-03-11 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to buy Common Stock) | −7,000 | 85,513 | ||
| 2021-03-05 | GREY MICHAEL G Director | Exercise or conversion | +5,000 | $26.49 | $132K | 47,840 |
| 2021-03-05 | GREY MICHAEL G Director | Sale | −5,000 | $76.28 | $381K | 42,840 |
| 2021-03-05 | GREY MICHAEL G Director | Exercise or conversion · Stock Option (Right to buy Common Stock) | −5,000 | 0 | ||
| 2021-03-04 | BIENAIME JEAN JACQUES Chief Executive Officer | Other acquisition | +100 | $77.94 | $8K | 295,652 |
Page 32 of 36 · 707 trades